Stocks · News reference
McKesson Buys Precision Medicine to Expand Clinical Research and Commercialization
McKesson will acquire Precision Medicine Group for $2.25 billion, expanding its clinical research and drug commercialization services.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 25, 2026, 3:31 PM
- Checked
- Aug 25, 2026, 3:31 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Barclays Maintains Overweight on McKesson, Raises Price Target to $1000
Barclays analyst Glen Santangelo maintains McKesson (NYSE:MCK) with a Overweight and raises the price target from $925 to $1000.
Read original at benzingaRBC Capital Initiates Coverage On McKesson with Sector Perform Rating, Announces Price Target of $845
RBC Capital analyst Ryan Halsted initiates coverage on McKesson (NYSE:MCK) with a Sector Perform rating and announces Price Target of $845.
Read original at benzinga